Description
Elromo 50 mg contains Eltrombopag, a thrombopoietin receptor (TPO-R) agonist that stimulates bone marrow to increase platelet production. It is widely prescribed in hematology for managing low platelet counts caused by various underlying conditions.
🔬 Mechanism of Action
Eltrombopag binds to the thrombopoietin receptor on hematopoietic stem cells in the bone marrow. As a result, it promotes the proliferation and differentiation of megakaryocytes, leading to increased platelet production and improved clotting ability.
💊 Indications
Elromo 50 mg is indicated for:
- Chronic Immune Thrombocytopenia (ITP) in patients with insufficient response to other therapies
- Severe Aplastic Anemia (SAA) in patients with inadequate response to immunosuppressive therapy
- Thrombocytopenia in Chronic Hepatitis C to enable antiviral therapy
📌 Key Features
- Strength: 50 mg
- Dosage Form: Oral tablet
- Therapeutic Class: Thrombopoietin Receptor Agonist
- Administration: Taken once daily on an empty stomach (as prescribed)
- Monitoring: Regular platelet count and liver function tests required
⚕️ Benefits
- Increases platelet counts effectively
- Reduces risk of bleeding complications
- Oral therapy for patient convenience
- Helps reduce dependency on platelet transfusions
⚠️ Precautions
- Risk of liver function abnormalities
- Dose adjustments based on platelet response
- Increased risk of thrombosis if platelet count becomes too high
- Regular monitoring essential during treatment
- Use strictly under hematologist supervision
Elromo 50 mg (Eltrombopag Tablets) provides an effective treatment option for managing chronic thrombocytopenia and related conditions, supporting improved platelet counts and better patient outcomes under specialized medical care.
